CR Boya Bio-pharmaceutical, China Resources Pharmaceutical subsidiary, posts 77.28% drop in H1 net profit attributable to shareholders to RMB 51.19 millionPUBT·Aug 21 at 03:52 AM300294+1.28%
BOYA BIOLOGY has continuously received a Wind ESG A rating, with a comprehensive score of 7.16同壁财经·May 30 at 10:02 AM300294+1.28%
China Resources Pharma's subsidiary China Resources Boya Biology earned 113 million RMB for the year, a decline of 71.6%AASTOCKS·Mar 22 at 12:04 AM5888600.00%03320-1.40%
China Resources Pharma's recombinant coagulation factor IX has received the clinical trial approval notice for drugs in mainland ChinaAASTOCKS·Feb 24 at 10:29 PM588130+0.19%159892+1.35%
CHINARES PHARMA subsidiary BOYA BIOLOGY expects a significant decrease in annual net profit due to impairment reductionAASTOCKS·Feb 1 at 03:51 AM03320-1.40%300294+1.28%
China Resources Pharmaceutical's subsidiary BOYA BIOLOGY earned 343 million RMB in the first nine months, a decline of 16.8%AASTOCKS·Oct 27, 2025 at 09:16 AM300294+1.28%
BOYA BIOLOGY: Completed the transfer of 80% equity in Jiangxi Boya Xinhao Pharmaceutical Co., LtdZhitong·Sep 9, 2025 at 03:58 AM300294+1.28%
BOYA BIOLOGY released its performance for the first half of the year, with a net profit attributable to the parent company of 225 million yuan, a decrease of 28.68%Zhitong·Aug 22, 2025 at 03:41 AM300294+1.28%
BOYA BIOLOGY has established a single plasma collection company in Inner MongoliaZhitong·Jun 26, 2025 at 09:13 PM300294+1.28%
CHINARES PHARMA's subsidiary BOYA BIOLOGY's blood plasma collection station has been issued a business license by the Market Supervision Administration of Dalat QiAASTOCKS·Jun 26, 2025 at 03:31 AM03320-1.40%300294+1.28%
BOYA BIOLOGY plans to jointly invest with Chengdu Hengnashun to establish a company to enhance the supply capacity of raw plasmaZhitong·May 30, 2025 at 06:11 AM300294+1.28%
BOYA BIOLOGY: Approved for the supplemental application of intravenous immunoglobulin drugZhitong·May 30, 2025 at 05:34 AM300294+1.28%
BOYA BIOLOGY: Human Immunoglobulin (pH4) has obtained the drug registration certificate from the Dominican RepublicZhitong·May 27, 2025 at 03:23 AM300294+1.28%
